Assessment of antidiabetic potential of Shilajatvadi Lauha processed with Daruharidra in streptozotocin-nicotinamide-induced diabetic rats
Autor: | Thakur Rakesh Singh, Laxmi Narayan Gupta, Neeraj Kumar, Vikas Kumar |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: | |
Zdroj: | Indian Journal of Health Sciences and Biomedical Research KLEU, Vol 9, Iss 3, Pp 308-314 (2016) |
Druh dokumentu: | article |
ISSN: | 2542-6214 2542-6222 2349-5006 |
DOI: | 10.4103/2349-5006.196334 |
Popis: | Objectives: To assess the antidiabetic potential of Shilajatvadi Lauha (SL) processed with Daruharidra (modified SL [MSL]) in streptozotocin (STZ)-nicotinamide (NA)-induced diabetic rats. Materials and Methods: Animals were divided into diabetic and nondiabetic groups. Type 2 diabetes in rats was induced with a single dose of STZ (65 mg/kg) NA (110 mg/kg) intraperitoneal diabetic rats were treated with formulation MSL (10, 30, and 100 mg/kg) and glibenclamide (10 mg/kg) once daily for 14 days orally. After 14 days treatment, fasting blood glucose and plasma insulin were assayed. Different biochemical parameters such as total cholesterol (TC), triglycerides (TGs), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and very LDL-C (VLDL-C) were also examined. Results: MSL significantly lowered the blood glucose and increases insulin level, which was comparable to the standard antidiabetic drug, glibenclamide. Treatment with MSL showed a significantly reduction in the levels of TC, TG, LDL-C, and VLDL-C and increases the level of HDL-C. Conclusion: MSL possess significant antidiabetic and antihyperlipidemic activity in Type 2 diabetes mellitus rats. The results are encouraging and further studies can be used to evaluate the exact mechanism of action to develop a novel molecule that will benefit the ailing. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |